CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM048272
035-os BibID:PMID:24131338
Első szerző:Farkas Klaudia
Cím:Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy / Klaudia Farkas, Péter László Lakatos, Ferenc Nagy, Zoltán Szepes, Pál Miheller, Mária Papp, Károly Palatka, Anita Bálint, Renáta Bor, Tibor Wittmann, Tamás Molnár
Dátum:2013
ISSN:0036-5521
Megjegyzések:Abstract Background. Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. The RASH study revealed that previous use of biological therapy and dose intensification are associated with restarting of biological therapy in Crohn's disease. The aim of the study was to assess the disease course and frequency of relapse of ulcerative colitis (UC) following discontinuation of infliximab in patients with remission and to determine predictive factors for relapse. Patients and methods. Fifty-one UC patients who had achieved clinical remission following 1 year of infliximab therapy and for whom infliximab was then discontinued participated in this prospective observational study. 15.7% of the patients received infliximab before the 1-year period of biological therapy analyzed in the study. Biological therapy was restarted in case of recurrent clinical activity. Data were collected from four Hungarian IBD centers. Results. Thirty-five percent of the patients needed to be retreated with infliximab within 1 year after treatment cessation. Logistic regression analysis revealed that previous biological therapy (p = 0.021) was associated with the need of restarting infliximab. None of the data relating to patients' demographic and clinical characteristics, concomitant therapy and CRP level showed association with the need for restarting biological therapy. Conclusions. Biological therapy was restarted at a median of 4 months after discontinuation in more than every third UC patients who had been in clinical remission following 1 year of infliximab therapy. Response to retreatment with infliximab was favorable in the majority of the patients who relapsed
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
infliximab therapy
discontinuation
ulcerative colitis
Megjelenés:Scandinavian Journal of Gastroenterology. - 48 : 12 (2013), p. 1394-1398. -
További szerzők:Lakatos Péter (Semmelweis Egyetem) Nagy Ferenc Szepes Zoltán Miheller Pál Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Bálint Anita Bor Renáta Wittmann Tibor Molnár Tamás
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM028429
Első szerző:Fischer Simon
Cím:ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases / Fischer Simon, Lakatos Peter Laszlo, the Hungarian IBD Study Group, Lakatos Laszlo, Kovacs Agota, Molnar Tamas, Altorjay Istvan, Papp Maria, Szilvasi Aniko, Tulassay Zsolt, Osztovits Janos, Papp Janos, Demeter Pal, Schwab Richard, Tordai Attila, Andrikovics Hajnalka
Dátum:2007
ISSN:0036-5521
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Scandinavian Journal Of Gastroenterology. - 42 : 6 (2007), p. 726-733. -
További szerzők:Lakatos Péter (Semmelweis Egyetem) Lakatos László (Veszprém) Kovács Ágota Molnár Tamás (orvos Szeged) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Szilvási Anikó (1977-) (molekuláris biológus) Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Osztovits János Papp János (Budapest) Demeter Pál Schwab, Richard Tordai Attila Andrikovics Hajnalka The Hungarian IBD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM043061
035-os BibID:PMID:22935014
Első szerző:Horváth Gábor (Semmelweis Kórház, Miskolc)
Cím:Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? / Gábor Horváth, Klaudia Farkas, Renáta Hollósi, Ferenc Nagy, Zoltán Szepes, Mária Papp, Károly Palatka, Pál Miheller, László Lakatos, Tamás Szamosi, Tibor Nyári, Tibor Wittmann, Tamás Molnár
Dátum:2012
ISSN:0036-5521
Megjegyzések:Inflammatory bowel diseases (IBD) have a huge impact on the patients' lives and require continuous medication and long-term medical follow-up. The Short Form Health Survey (SF-36) is a commonly used questionnaire measuring health-related quality of life (HRQOL). Our aim was to evaluate whether HRQOL influences medication adherence and vice versa in IBD patients, and to find relationships between demographic parameters, therapeutic modalities and non-adherence or HRQOL. PATIENTS AND METHODS: Five hundred ninety-two IBD patients treated at six Hungarian tertiary centers were enrolled. Patients completed the SF-36 questionnaire and a medication adherence report scale during their visits. The associations between demographic parameters, HRQOL, different kinds of therapies and non-adherence were analyzed. RESULTS: The most affected dimension was physical functioning and least affected were the social functions. About 42.7% of the patients revealed their HRQOL to be acceptable. About 74.6% of the patients believed that the prescribed medications actually improved their HRQOL. Diarrhea was the most common and most severe symptom during the course of the disease. Non-adherence was reported in 13.4% of the patients. 'Forgetting to take the medication' was the main reason for non-adherence in 67.6% of the cases. Medication adherence was significantly higher among nonsmoker patients, and also in the case of immunomodulator therapy. There was no association between the sum of HRQOL and different subscores and non-adherence. CONCLUSION: Inflammatory bowel disease is associated with low HRQOL, which is not affected by drug therapy. The impaired quality of life in IBD is mainly influenced by the disease itself.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Scandinavian Journal of Gastroenterology. - 47 : 11 (2012), p. 1298-1303. -
További szerzők:Farkas Klaudia Hollósi Renáta Nagy Ferenc (orvos Szeged) Szepes Zoltán Papp Mária (1975-) (belgyógyász, gasztroenterológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Miheller Pál Lakatos László (Veszprém) Szamosi Tamás Nyári Tibor Wittmann Tibor Molnár Tamás (orvos Szeged)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1